Array BioPharma gets $3 million milestone from AstraZeneca

By Lisa Kerner

Charlotte, N.C., Sept. 14 - Array BioPharma Inc. received a $3 million payment from AstraZeneca, triggered by dosing of the first patient in a phase 2 trial comparing AZD6244 (ARRY-142886) to temozolomide in the treatment of stage 3/ 4 melanoma patients.

AstraZeneca plans to enroll up to 180 patients at 40 centers worldwide and to begin additional phase 2 studies in other tumors later this year.

Array is a Boulder, Colo., biopharmaceutical company.

AstraZeneca is an international health care business located in Wilmington, Del.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.